Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223944 · ClinicalTrials.gov registry record · Phase 3
A Gaucher Disease Gene Therapy Trial With FLT201
A Phase 3 study, sponsored by Spur Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT07223944: Recruiting Phase 3 study, sponsored by Spur Therapeutics.
NCT07223944 is a Phase 3 study that is actively recruiting participants, run by Spur Therapeutics. The registered enrollment target is 45 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223944, a Phase 3 study, is actively recruiting participants, sponsored by Spur Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. The study aims to confirm the efficacy and safety of FLT201 in this population after discontinuation of ERT/SRT.
Primary Outcome
Proportion of participants with stable hemoglobin concentration (decrease from baseline of no more than 1.5 g/dL) at Week 52
Interventions
- GENETIC FLT201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-04-07 |
| Est. Completion | 2032-10-01 |
| Phase | Phase 3 |
What NCT07223944 shows while recruiting
NCT07223944 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which FLT201 is the first listed.
NCT07223944 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07223944 about?
NCT07223944 is a clinical study titled "A Gaucher Disease Gene Therapy Trial With FLT201". This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. The study aims to confirm the efficacy and safety of FLT...
What is the current status of trial NCT07223944?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2026-04-07. Estimated completion is 2032-10-01.
What interventions are being tested in trial NCT07223944?
The interventions under investigation include: FLT201 (GENETIC).
Who is sponsoring clinical trial NCT07223944?
This trial is sponsored by Spur Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07223944's enrollment target sits among peer trials
45 1870th of 2000 higher than 127 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI